Safety of trovafloxacin in treatment of lower respiratory tract infections

  • D. Williams
  • S. Hopkins


Safety and toleration of oral trovafloxacin has been assessed in Phase III trials in patients with acute lower respiratory tract infections. Patients were treated orally with either trovafloxacin 100 or 200 mg (n=881) or a comparator (500 or 1000 mg amoxicillin, or 625 mg amoxicillin/clavulanic acid;n=593). Adverse events were recorded in 112 (12.7%) trovafloxacin- and 74 (12.5%) comparator-treated patients. Frequency of effects on the autonomic nervous, musculoskeletal, respiratory, special senses, urinary and reproductive systems was <1%. Photosensitivity reactions were not reported in trovafloxacin-treated patients. Central or peripheral nervous system adverse effects (headache and dizziness) were slightly more common in trovafloxacin-treated patients (4.4% vs 1.9%). Patients treated with comparators experienced gastrointestinal events more frequently (6.1% vs 8.3%). Comparable incidences of adverse events were reported in patients ≥65-years-old. Most events were mild to moderate in severity. Treatment was discontinued because of an adverse event in 18 (2%) trovafloxacin- and four (0.7%) comparator-treated patients. Despite the high prevalence of risk factors, serious adverse events were rare and the mortality rate over the 35-day study period was low: trovafloxacin 0.8%, comparator agents 1.5%. Laboratory test abnormalities were recorded in less than 1% of patients in either treatment group.


Amoxicillin Peripheral Nervous System Reproductive System Lower Respiratory Tract Infection System Adverse Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pechère J-C: Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:405–412Google Scholar
  2. 2.
    Edelstein PH, Edelstein MAC, Ren J, Polzer R, Gladue RP: Activity of trovafloxacin (CP-99,219) againstLegionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs withL. pneumophila pneumonia. Antimicrobial Agents and Chemotherapy (1996) 40:314–319PubMedGoogle Scholar
  3. 3.
    Vincent J, Teng R, Dogolo L, Baris BA, Willavize SA: Single-and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in man. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:427–430Google Scholar
  4. 4.
    Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer SJ, Friedman HL: Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 75–80Google Scholar
  5. 5.
    Fischman AJ, Babich JW, Alpert NM, Vincent J, Wilkinson RA, Callaghan RJ, Correia JA, Rubin RH: Pharmacokinetics of 18F-labeled trovafloxacin in normal andEscherichia coli- infected rats and rabbits studied with positron emission tomography. Clinical Microbiology and Infection (1997) 3:63–71PubMedGoogle Scholar
  6. 6.
    Andrews JM, Honeybourne D, Brenwald NP, Bannerjee D, Iredale M, Cunningham D, Wise R: Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 797–802PubMedGoogle Scholar
  7. 7.
    Hooper DC, Wolfson JS: Adverse effects. In: Hooper DC, Wolfson JS (eds) Quinolone antimicrobial agents. American Society for Microbiology, Washington DC (1993) pp. 489–512Google Scholar
  8. 8.
    Jüngst G, Mohr R: Overview of postmarketing experience with ofloxacin in Germany. Journal of Antimicrobial Chemotherapy (1988) 22, Supplement C: 167–175Google Scholar
  9. 9.
    Reiter C, Pfeiffer M, Hullman N: Brief report: safety of ciprofloxacin based on phase IV (“Anwendungsbeobachtung”) in the Federal Republic of Germany. American Journal of Medicine (1989) 87, Supplement A: 103–106PubMedGoogle Scholar
  10. 10.
    Haria M, Lamb HM: Trovafloxacin. Drags (1997) 54:435–445Google Scholar
  11. 11.
    O'Doherty B, Daniel R, the Trovafloxacin Bronchitis Study Group: Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:441–446Google Scholar
  12. 12.
    Léophonte P, Baldwin RJT, Pluck N: Trovafloxacin versus amoxicillin/clavulanic acid treatment of acute exacerbations of chronic bronchitis. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:434–440Google Scholar
  13. 13.
    Trémolières F, de Kock F, Pluck N: Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:447–453Google Scholar
  14. 14.
    Carbon C, Rubinstein E (eds) Sparfloxacin monograph. Adis International (1994) Chester, p. 45Google Scholar
  15. 15.
    Rizk E: The US clinical experience with lomefloxacin, a new once-daily fluoroquinolone. American Journal of Medicine (1992) 92, Supplement 4A: 130–135Google Scholar
  16. 16.
    Gonzalez JP, Henwood JM: Pefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1989) 37:628–668PubMedGoogle Scholar
  17. 17.
    Norrby SR: Side-effects of quinolones: comparisons between quinolones and other antibiotics. European Journal of Clinical Microbiology & Infectious Diseases (1991) 19:378–383Google Scholar
  18. 18.
    Iravani A: Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections. American Journal of Medicine (1991) 94, Supplement A: 89–96Google Scholar
  19. 19.
    Stahlmann R: Safety profile of the quinolones. Journal of Antimicrobial Chemotherapy (1990) 26, Supplement D: 31–44Google Scholar
  20. 20.
    Mayne JT, Johnson NJ, Kluwe WM, Lencoski DL, Polzer RJ: A study of the phototoxic potential of trovafloxacin in BALB/c mice. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 51–55PubMedGoogle Scholar
  21. 21.
    Maesen FPV, Teengs JP, Baur C, Davies BI: Quinolones and raised plasma concentrations of theophylline. Lancet (1984) ii: 530Google Scholar
  22. 22.
    Wijnands WJA, VanHerwaarden CLA, Vree T: Enoxacin raises plasma concentrations of theophylline. Lancet (1984) ii: 108–109Google Scholar
  23. 23.
    Wijnands WJA, Vree T, VanHerwaarden CLA: The influence of quinolone derivatives on theophylline clearance. British Journal of Clinical Pharmacology (1986) 22:677–683PubMedGoogle Scholar
  24. 24.
    Vincent J, Teng R, Dogolo LC, Willavize SA, Friedman HL: Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 81–86Google Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • D. Williams
    • 1
  • S. Hopkins
    • 1
  1. 1.Department of Clinical ResearchCentral Research Division, Pfizer IncGrotonUSA

Personalised recommendations